EMSA

EMSA
Name	Electrophoretic Mobility Shift Assay
Abbreviation	EMSA
Type	Biochemical assay
Purpose	Detect DNA–protein and RNA–protein interactions
Introduced	1969
Developers	B. D. H. Hames; R. D. Burgess; P. K. Das

EMSA

EMSA is a biochemical technique used to detect and characterize interactions between nucleic acids and proteins by observing shifts in electrophoretic mobility. Originally established in the late 1960s, the assay links the behavior of labeled DNA or RNA probes to binding by transcription factors, chromatin proteins, and ribonucleoproteins from sources such as HeLa cell extracts, purified recombinant factors, or nuclear fractions from Saccharomyces cerevisiae. Widely applied across molecular biology, biochemistry, and clinical research, EMSA complements methods like Chromatin immunoprecipitation and Surface plasmon resonance for probing specificity, affinity, and complex stoichiometry.

Overview

EMSA separates free nucleic acid probes from probe–protein complexes using native gel electrophoresis, typically polyacrylamide or agarose, under non-denaturing conditions described in protocols from Cold Spring Harbor Laboratory and published in journals such as Proceedings of the National Academy of Sciences. Probes are end-labeled with isotopes (e.g., 32P), fluorescent dyes (e.g., Cy5), or biotin for detection by chemiluminescence with reagents from suppliers like Thermo Fisher Scientific. Binding reactions often include competitor oligonucleotides, specific antibodies from vendors such as Abcam or Santa Cruz Biotechnology, and cofactors like Mg2+ or ATP dependent on factors derived from organisms such as Escherichia coli or Drosophila melanogaster.

History and Development

EMSA traces origins to electrophoretic mobility observations reported in the 1960s and formalized by investigators associated with institutions including University of Cambridge and Max Planck Institute laboratories. Early adoption by groups working on lac operon regulation and viral transcription—groups like those led by researchers affiliated with Columbia University and Stanford University—helped establish EMSA as a standard assay alongside pioneering techniques such as DNase I footprinting and filter binding assays. Subsequent methodological refinements incorporated advances from innovators at Cold Spring Harbor Laboratory Press and commercialization by companies such as GE Healthcare and Bio-Rad Laboratories, enabling higher-throughput variants used in projects like the ENCODE Project.

Techniques and Methodology

Standard EMSA workflow includes probe design based on sequences from databases like GenBank or Ensembl and synthesis by firms including Integrated DNA Technologies. Labeled probes employ isotopic labeling protocols refined by laboratories at Harvard Medical School or fluorescent conjugation approaches popularized in studies from Massachusetts Institute of Technology. Binding reactions are optimized with buffers derived from recipes in manuals from Nature Protocols and often include blocking agents such as poly(dI-dC) first applied in experiments at University of California, Berkeley. Electrophoresis uses native gels prepared with reagents from Sigma-Aldrich and instrumentation from Bio-Rad Laboratories or Thermo Fisher Scientific. Detection strategies vary: autoradiography aligning with equipment from GE Healthcare Life Sciences, fluorescence imaging using scanners by LI-COR Biosciences, or chemiluminescent detection paired with streptavidin–horseradish peroxidase conjugates produced by companies like Promega.

Quantitative EMSA integrates densitometry methods developed in bioinformatics groups at European Molecular Biology Laboratory and curve-fitting approaches informed by models from Michaelis-Menten-style binding analyses used in publications from Journal of Biological Chemistry. Supershift assays employ antibodies to specific proteins characterized by studies from National Institutes of Health researchers to confirm identity, while competition assays use cold competitor oligonucleotides designed from motifs cataloged by consortia such as JASPAR.

Applications

EMSA has broad application across research fields exemplified by studies at Johns Hopkins University, Salk Institute, and Wellcome Trust Sanger Institute. Common uses include identifying transcription factor binding by proteins like p53, NF-κB subunits, and CREB; characterizing viral nucleoproteins from HIV or Influenza A virus; and assessing RNA–protein interactions for factors such as HuR and TRBP. Clinical and diagnostic applications appear in investigations into biomarkers for diseases studied at centers like Mayo Clinic and Cleveland Clinic. EMSA also supports synthetic biology projects at institutions including MIT and Caltech for engineered regulators and is employed in drug discovery by pharmaceutical companies such as Pfizer and Novartis to screen small molecules that disrupt nucleic acid–protein interfaces.

Interpretation and Limitations

Interpretation relies on comparing mobility shifts against controls pioneered in protocols from Cold Spring Harbor Laboratory and validated by groups at European Molecular Biology Organization. Shifts indicate complex formation but do not alone define binding site location; complementary techniques like DNase I footprinting or Chromatin immunoprecipitation sequencing are often required. Limitations include artifacts from probe secondary structure reported in studies from University College London and non-physiological binding induced by extract composition documented by researchers at McGill University. Sensitivity constraints differ between radioactive and fluorescent detection, with isotopic methods historically offering higher sensitivity described in articles in Nature.

Variants and Related Assays

Variants include supershift assays using antibodies characterized by American Type Culture Collection resources, competition EMSA popularized in methodological papers in Methods in Enzymology, and high-throughput adaptations such as microfluidic EMSA platforms developed at Stanford University and fluorescence anisotropy assays from groups at University of Oxford. Related assays include Surface plasmon resonance, Isothermal titration calorimetry, Filter binding assay, Chromatin immunoprecipitation, and DNAse I footprinting, each providing complementary information on affinity, kinetics, or in vivo occupancy as demonstrated in comparative studies from institutions such as University of California, San Francisco and Yale University.

Category:Biochemical assays